Moderna, Inc. MRNA
269.00 USD +14.81 (+5.83%)
At closeNov 9, 2026, 7:57 PM EST
270.99 +1.99 +0.74%
After hours · Nov 9, 7:57 PM ET
253.50 Day range 280.80
22.36 52-week range 269.00
- YTD
- +812.17%
- 1 year
- +996.17%
News
benzinga.com Goldman Sachs Maintains Neutral on Moderna, Raises Price Target to $195 Goldman Sachs analyst Salveen Richter maintains Moderna (NASDAQ:MRNA) with a Neutral and raises the price target from $137 to $195.
benzinga.com Piper Sandler Reiterates Overweight on Moderna, Raises Price Target to $305 Piper Sandler analyst Edward Tenthoff reiterates Moderna (NASDAQ:MRNA) with a Overweight and raises the price target from $230 to $305.
benzinga.com Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain? Biotech ETFs face key FDA catalysts as Summit Therapeutics' decision and the Hims-Lilly GLP-1 deal put XLV, IBB and XBI in focus.
fool.com BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era. BioNTech and Moderna are working to reduce their dependence on COVID-19 vaccines through expanding pipelines in cancer treatment and other diseases. Moderna's latest quarterly results showed…
fool.com Moderna: 3 Key Takeaways for Long-Term Investors Moderna raised full-year 2026 revenue growth guidance to 15% to 25%. Intismeran reduced the risk of melanoma recurrence or death by 42% in Phase 3.
benzinga.com Moderna Stuns Wall Street With Surprise Profit, Raises Outlook Moderna (MRNA) jumps as Q3 earnings swing to a surprise profit of $0.38/share on strong global vaccine sales and cost cuts.- benzinga.com Moderna, JFrog, TransMedics, Ubiquiti And Other Big Stocks Moving Higher On Friday U.S. stocks rose, Nasdaq gained ~400 points. Moderna jumped 9.1% on strong Q3 results and higher FY26 guidance; other stocks rallied on results and deals.
fool.com Moderna Just Gave Investors Yet Another Thing to Cheer About Moderna earned a surprise profit in the third quarter, while analysts expected a loss of more than $1 per share. Management raised its full-year revenue growth outlook to 15% to 25% and cut its R&D…
schaeffersresearch.com Nasdaq Futures Jump as Volatile Week Continues Stock futures are trading mixed as Wall Street digests today's nonfarm payrolls data and yesterday's steep selloff
benzinga.com Moderna Q3 2026 Earnings Call Transcript Moderna (NASDAQ:MRNA) reported third-quarter financial results on Friday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
zacks.com Moderna (MRNA) Q3 Earnings and Revenues Top Estimates Moderna (MRNA) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of a loss of $1.1 per share. This compares to a loss of $0.51 per share a year ago.
barrons.com Moderna Stock Is Up 700% on Cancer Vaccine Hype. Earnings Reveal That Covid Still Counts. Moderna posts higher-than-expected revenue as results get a lift from international Covid vaccine demand.
wsj.com Moderna Lifts Full-Year Outlook, Swings to Quarterly Profit The biopharmaceutical company said Friday it now expects total revenue growth of 15% to 25% for the year, compared with a previous outlook for up to 10% growth.
reuters.com Moderna lifts annual revenue forecast on strong COVID vaccine demand overseas Nov 6 (Reuters) - Moderna (MRNA.
cnbc.com Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction Moderna smashed third-quarter revenue and earnings estimates and hiked its outlook for full-year sales growth. The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous…
benzinga.com Moderna Raises FY2026 Sales Guidance from $2.138B to $2.236B-$2.430B vs $2.102B Est Moderna (NASDAQ:MRNA) raises FY2026 sales outlook from $2.138 billion to $2.236 billion-$2.430 billion vs $2.102 billion estimate.
benzinga.com Moderna Q3 EPS $0.38 Beats $(1.26) Estimate, Sales $1.313B Beat $885.051M Estimate Moderna (NASDAQ:MRNA) reported quarterly earnings of $0.38 per share which beat the analyst consensus estimate of $(1.26) by 130.16 percent. This is a 174.51 percent increase over losses of $(0.51)…
benzinga.com Moderna Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts Moderna, Inc. (NASDAQ:MRNA) will release earnings for its third quarter before the opening bell on Friday, Nov. 6.
benzinga.com Moderna Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts Moderna reports Q3 earnings Friday, with analysts expecting a $1.25 loss per share and $890M revenue; shares fell 6.6% after vaccine approvals.
benzinga.com Stock Market: Will S&P 500 Open Up or Down Today? Will the S&P 500 open higher? Polymarket odds hit 62% as Wall Street eyes jobs data and a tech rebound.
benzinga.com Moderna Says Health Canada Authorizes mFLUSIVA And mCOFLU For Adults 50 Years Of Age And Older Canada becomes the first country to authorize both Moderna's mRNA seasonal influenza vaccine, mFLUSIVA®, and combination influenza and COVID-19 vaccine, mCOFLU®CAMBRIDGE, MA / ACCESS Newswire /…
benzinga.com Enbridge, Moderna On Deck Friday As Demand, Vaccine Pipeline Face Test Enbridge headlines Friday’s reports, with investors weighing whether resilient pipeline utilization can offset a softer revenue comparison. Moderna, Brookfield Asset Management, Humana, Vistra, PPL,…
benzinga.com Moderna's Data From Its Current Phase 1/2 Trial Of mRNA-2808 Selected For Oral Presentation At 68th American Society Of Hematology Annual Meeting Moderna, Inc. (NASDAQ:MRNA) today announced that initial clinical data from its ongoing Phase 1/2 study of mRNA-2808 have been selected for oral presentation at the 68th American Society of…
benzinga.com Wayfair, Lendingtree, Bruker, Zimmer Biomet And Other Big Stocks Moving Higher On Wednesday U.S. stocks surged, led by Wayfair after strong results; Cricut, Array Technologies, Clear Secure and others also posted double-digit gains.
fool.com Moderna's Cancer Vaccine Is Incredibly Promising, but This Could Be a Major Obstacle to Its Success Moderna and Merck have developed a cancer vaccine that has been highly effective in treating melanoma patients. In a late-stage trial, it reduced the risk of death and melanoma recurrence by 42% when…
247wallst.com Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Despite New Phase 3 Trial Three of the biggest names in pharma and vaccines are trading against their own headlines. Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is at $231.
fool.com Could Investing in Moderna's Stock Double Your Money? Intismeran is a promising cancer vaccine that has been highly effective when paired with Keytruda. Moderna is working with Merck on evaluating the vaccine for various types of cancers.
defenseworld.net Moderna, Inc. $MRNA Stock Sold by Bank Julius Baer & Co. Ltd Zurich Bank Julius Baer and Co. Ltd Zurich reduced its stake in shares of Moderna, Inc. (NASDAQ: MRNA) by 35.0% in the undefined quarter, according to its most recent 13F filing with the Securities and…
zacks.com Buy Moderna Stock Before Q3 Earnings? Here's What to Know Moderna MRNA is scheduled to report third-quarter 2026 earnings on Nov. 6, before the opening bell. The Zacks Consensus Estimate for sales is pinned at $888.8 million, while that for earnings is…
fool.com If Moderna's CEO Is Right, the Stock's Rally Could Just Be Getting Started Cancer vaccine intismeran has been highly effective in clinical trials when paired with Merck's Keytruda. In a recent trial, the combination reduced the risk of death or recurrence for melanoma…
benzinga.com Tempus AI Earnings Ahead: Is TEM Set Up To Pop or Drop? Tempus AI, a company that Cathie Wood has invested in, will publish its financial results this week as its volatility continues.
benzinga.com Earnings Volatility Watch: 10 Stocks Are Set to Swing More Than 10% This Week Ten stocks carry implied earnings moves above 10% next week, led by Moderna and AppLovin. Five are tech names hit in Friday's chip rout.
benzinga.com Merck One of Top Large-Cap Biopharma Picks-Analyst Merck beats Q3 estimates on oncology strength and raised guidance, while Guggenheim eyes pipeline progress ahead of Keytruda patent loss.
benzinga.com This M&T Bank Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday Analysts downgraded M&T Bank, Bank of Hawaii, HubSpot, Abbott and Moderna; Bank of Hawaii cut its target, while HubSpot’s rose.
benzinga.com William Blair Takes a Shot at Moderna Stock: Downgrade to Market Perform After a 545% Run Moderna shares are trading lower Tuesday after William Blair downgraded the stock to Market Perform on Monday, citing valuation concerns.- benzinga.com Piper Sandler Reiterates Overweight on Moderna, Raises Price Target to $230 Piper Sandler analyst Edward Tenthoff reiterates Moderna (NASDAQ:MRNA) with a Overweight and raises the price target from $167 to $230.
benzinga.com Moderna Stock Saga: Leaked Data, a Panicked Influencer and Perfect Timing Moderna’s stock went on a wild ride last week that included a data leak and a dramatic tale from a social media influencer.
benzinga.com MercadoLibre, Banco Bradesco, Itaú Unibanco And Other Big Stocks Moving Lower In Monday’s Pre-Market Session Brazilian stocks plunged premarket after Lula's reelection, led by XP (-46%), Inter & Co (-34.7%), StoneCo (-33.8%) and MercadoLibre (-14.1%).
benzinga.com Moderna Stock Slides Again Friday: What's Going On? Moderna slides in premarket trading post ESMO data leak, despite Phase 3 vaccine trial showing a 42% cut in melanoma recurrence.
benzinga.com Deckers Outdoor Posts Mixed Q2 Results, Joins BayCom, Five Point Holdings And Other Big Stocks Moving Lower In Friday’s Pre-Market Session U.S. stock futures fell, led by Deckers down 9% after mixed results and reduced FY27 guidance. BayCom, ROLR, Trulieve and others also slid premarket.- benzinga.com Merck And Moderna Report Phase 3 Melanoma Trial Results For Personalized mRNA Cancer Therapy; Intismeran Plus KEYTRUDA Cuts Melanoma Recurrence Or Death Risk By 42% Intismeran plus KEYTRUDA significantly reduced the risk of recurrence or death by 42% (HR=0.58 [95% CI, 0.45–0.75]; two-sided p<0.001) compared to KEYTRUDA alone for patients with completely resected…
benzinga.com Why Is Moderna Stock Sinking Thursday? Moderna stock plummeted 25% following an alleged ESMO 2026 abstract leak showing lower-than-expected melanoma vaccine Phase 3 efficacy.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Profusa (NASDAQ:PFSA) shares moved upwards by 35.4% to $1.15 during Thursday's regular session. Karyopharm Therapeutics (NASDAQ:KPTI) shares increased by 29.12% to $0.55. The company's market…
benzinga.com FDA Lifts Three-Year Freeze On Arbutus Biopharma's Hepatitis B Study The FDA lifts its 3-year clinical hold on Arbutus Biopharma's AB-101 hepatitis B drug candidate, clearing US clinical trials.- benzinga.com TD Cowen Maintains Hold on Moderna, Raises Price Target to $90 TD Cowen analyst Tyler Van Buren maintains Moderna (NASDAQ:MRNA) with a Hold and raises the price target from $40 to $90.
benzinga.com What's Going On With Moderna Stock Monday? Moderna shares are trading higher Monday ahead of detailed Phase 3 melanoma data due Saturday and after BofA raised its price target.
benzinga.com Nasdaq 100 Slides As Micron, SanDisk, CoreWeave Sink: Stock Market Today The Nasdaq 100 fell 1.5% at midday Friday as memory chips and AI-debt names sold off, while Fed Chair Warsh declined to rule out an October hike after hot CPI and PPI. WTI held near $96, the 10-year…
benzinga.com Nike, Moderna, Walmart Get a Lift as Traders Flee AI Stocks Concerns about tech companies overspending on AI prompted investors to rotate out of the trade and seek value elsewhere.- benzinga.com Fastenal To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday Analysts raised targets for TSM, MRNA, ALEC and WMT; cut AZZ, ARRY and ALGN targets, upgrading ARRY/WMT and downgrading ALGN.
- benzinga.com Goldman Sachs Maintains Neutral on Moderna, Raises Price Target to $137 Goldman Sachs analyst Salveen Richter maintains Moderna (NASDAQ:MRNA) with a Neutral and raises the price target from $120 to $137.